Although the profile is not precise enough to definitively diagnose Alzheimer’s, it offers a convenient way for doctors to determine which patients need advanced testing, according to the company.
Tag Archive for: brain wasting disease
UCLA researchers estimated annual spending of $2 billion for a low-end estimate of 86,000 patients receiving Leqembi, and $5.1 billion if around 216,000 eligible patients were treated with the drug.
An experimental Alzheimer’s drug developed by Eli Lilly slowed cognitive decline by 35% in a closely watched late-stage trial, the company said, raising hopes for a second effective treatment for the brain-wasting disease.
